Literature DB >> 33994240

Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.

Jessie R Chung1, Brendan Flannery2, Sara S Kim3, Manjusha Gaglani4, Chandni Raiyani5, Edward A Belongia6, Huong Q McLean7, Mary Patricia Nowalk8, Richard K Zimmerman9, Michael L Jackson10, Lisa A Jackson11, Emily T Martin12, Arnold S Monto13, Manish Patel14.   

Abstract

INTRODUCTION: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE.
METHODS: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE.
RESULTS: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups.
CONCLUSION: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33994240      PMCID: PMC8204739          DOI: 10.1016/j.vaccine.2021.05.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   4.169


  20 in total

1.  Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Authors:  Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

Review 2.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Authors:  Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres
Journal:  Expert Rev Vaccines       Date:  2017-06-09       Impact factor: 5.217

Review 3.  Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review.

Authors:  Vivian K Leung; Benjamin J Cowling; Shuo Feng; Sheena G Sullivan
Journal:  Euro Surveill       Date:  2016-04-21

4.  Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season.

Authors:  Brendan Flannery; Rebecca J Garten Kondor; Jessie R Chung; Manjusha Gaglani; Michael Reis; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Sara S Kim; Lenee Blanton; Krista Kniss; Alicia P Budd; Lynnette Brammer; Thomas J Stark; John R Barnes; David E Wentworth; Alicia M Fry; Manish Patel
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

5.  Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.

Authors:  Michael J Wu; Jessie R Chung; Sara S Kim; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Michael Reis; Madhava Beeram; Emily T Martin; Arnold S Monto; Mary Patricia Nowalk; Richard Zimmerman; Tammy A Santibanez; James A Singleton; Manish Patel; Brendan Flannery
Journal:  Vaccine       Date:  2021-02-15       Impact factor: 4.169

6.  Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019.

Authors:  Joshua D Doyle; Jessie R Chung; Sara S Kim; Manjusha Gaglani; Chandni Raiyani; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Angie Foust; Wendy Sessions; LaShondra Berman; Rebecca J Garten; John R Barnes; David E Wentworth; Alicia M Fry; Manish M Patel; Brendan Flannery
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-02-15       Impact factor: 35.301

7.  Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Authors:  Brendan Flannery; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Melissa A Rolfes; Sarah Spencer; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 20.999

8.  Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014.

Authors:  Brendan Flannery; Swathi N Thaker; Jessie Clippard; Arnold S Monto; Suzanne E Ohmit; Richard K Zimmerman; Mary Patricia Nowalk; Manjusha Gaglani; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; LaShondra Berman; Angie Foust; Wendy Sessions; Sarah Spencer; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-02-21       Impact factor: 17.586

9.  Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-22       Impact factor: 17.586

10.  Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.

Authors:  Brendan Flannery; Jessie R Chung; Swathi N Thaker; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Angie Foust; Wendy Sessions; LaShondra Berman; Sarah Spencer; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-02-17       Impact factor: 35.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.